Capecitabine
Antineoplastic (oral 5-FU prodrug)
Brand names: Xeloda
Oral health effects
Oral mucositis
Painful, ulcerative inflammation of the oral mucosa that can limit nutrition and serve as a portal for infection.
Mechanism: Direct cytotoxic injury to rapidly dividing mucosal epithelium.
Clinical management: Pre-treatment dental clearance, basic oral care protocols, bland rinses, topical analgesia; oncology coordination. Cryotherapy helps with some bolus regimens.
Infection & bleeding risk (myelosuppression)
Neutropenia and thrombocytopenia raise the risk of oral infection and bleeding.
Clinical management: Defer elective invasive care during neutropenic/thrombocytopenic nadirs; coordinate counts with oncology.
Taste change (dysgeusia)
Taste disturbance was reported in 14–16% of patients in label clinical-trial tables.
Clinical management: Reassure that taste changes are common during cancer therapy and usually improve after treatment; rule out oral candidiasis and dry mouth, keep the mouth clean (bland rinses), and suggest dietitian input if eating is affected.
Sources
- MASCC/ISOO clinical practice guidelines for the management of mucositis. Lalla RV, Bowen J, et al.. Cancer, 2014.
- Capecitabine prescribing information (FDA label) Quallent Pharmaceuticals Health LLC / DailyMed, 2025.
- A systematic review of dysgeusia induced by cancer therapies. Hovan AJ, Williams PM, Stevenson-Moore P, et al. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2010.